SEC Filing Summary: Amedica Corporation (8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Amedica Corporation on July 28, 2017. The report details the entry into a material definitive agreement involving a new term loan and the issuance of equity warrants. Note: The request metadata references "Sintx Technologies, Inc.", but the filing text explicitly identifies the registrant as "Amedica Corporation."
Key Financial Metrics and Transaction Details
- Debt Financing: The Company secured a $2.5 million term loan from North Stadium Investments, LLC.
- Interest Rate: 10% per annum.
- Repayment Terms: Monthly interest-only payments for 12 months; principal and accrued interest due in full 12 months from July 28, 2017.
- Collateral: The loan is secured by substantially all Company assets, junior to an existing security interest held by Hercules Capital, Inc.
- Equity Issuance: The Company issued a warrant to acquire up to 660,000 common shares at an exercise price of $0.42 per share with a 5-year term.
- Liquidity Impact: The filing does not provide specific pre-transaction cash balances or post-transaction liquidity metrics.
Material Changes and Related Party Transactions
The primary material change is the increase in debt obligations and potential equity dilution. The lender, North Stadium Investments, LLC, is owned and controlled by Dr. Sonny Bal, the Company's Chief Executive Officer and Chairman of the Board, constituting a related-party transaction. The securities were issued pursuant to exemptions under Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D.
Guidance, Risks, and Contingencies
The filing does not contain forward-looking guidance, revenue outlook, or management commentary regarding future operations. The primary risk disclosed is the creation of a direct financial obligation secured by substantially all Company assets, which is subordinate to existing debt held by Hercules Capital, Inc.
Key Facts for Investor Verification
- Verify the Company's current cash position to assess the ability to service the new $2.5 million debt and monthly interest payments.
- Confirm the terms of the existing senior security interest held by Hercules Capital, Inc. to understand the priority of claims on Company assets.
- Review the impact of the 660,000 warrant shares on potential future dilution at the $0.42 exercise price.
- Validate the related-party nature of the transaction with North Stadium Investments, LLC.